NEU Grand Library | TRNC Library


	NEU GRAND LIBRARY Opening Hours: Monday-Saturday, 08:00-20:00 \| E-mail: library@neu.edu.tr

You are not logged in

Show Basket

Home

Advanced Search

Back

Add to Basket

Brief display

MARC Display

Reserve

Comparing subcutaneous and sublingual immunotherapy: what do we know? (Bahceciler, Nerin Nadir)

Bibliographical information (record 266457)

Comparing subcutaneous and sublingual immunotherapy: what do we know?
Author:	Bahceciler, Nerin Nadir Search Author in Amazon Books
Publisher:	Lippincott Williams & Wilkins

Edition:	2012.
Classification:	WD300
URL:	http://library.neu.edu.tr:2048/login?url=http://dx.doi.org/10.1097/ACI.0b013e328358d5f2

Detailed notes

- Purpose of review Although allergen-specific sublingual (SLIT) and subcutaneous immunotherapy (SCIT) have been demonstrated to be clinically effective with similar immunological responses, head-to-head studies comparing those two modes of allergen administration in terms of onset of clinical improvement along with simultaneous immunological responses and underlying mechanisms of preventive effect are scarce. The present review will update current data on this issue. Recent findings Compared with SLIT, SCIT provides a rapid onset of clinical improvement by eliciting a simultaneous surge in production of T helper 1 (Th1) and T regulatory cell (Treg) cytokines and blocking antibodies. Similar immunological and clinical responses are evoked quite later, with no effect on Immunoglobulin G (IgG)4 levels during SLIT. Increases in TGF beta secretion due to nonrelevant allergens during SLIT may explain the preventive effect on new sensitizations. Summary SLIT and SCIT are both clinically effective in the treatment of respiratory allergic diseases with slight differences in the early phase in terms of onset of clinical efficacy and simultaneous immunological responses. Both SLIT and SCIT induce similar T-cell responses in time, but specific IgG4-blocking antibody responses are more prevalent following SCIT. Further head-to-head studies addressing the preventive effect of monotherapy and the efficacy and immunological responses of nonrelated multiallergen immunotherapy in polysensitized patients are warranted.